Clinical Education Hub

Hematology

Continuing Education on Hematology

The recent years have witnessed major advances in the treatment of benign rare blood disorders such as hemophilia, sickle cell disease (SCD), and cold agglutinin disease (CAD).

Moreover, new guidelines have been developed for the diagnosis and management of these blood disorders. Clinicians including hematologists and emergency department physicians need to remain up to date on the various aspects of management of these hematological disorders to diagnose, treat, and manage associated complications. Moreover, access to novel therapies remains challenging due to payer restrictions including step therapy policies. Hematologists and their care team need education on streamlining the prior authorization processes to prevent treatment delays.

Hematology

Certified Activity
Non-certified Activity
Resource
Patient Education
Expired Activity
Title
Availability
Format
Credits
Launch Date
Buttons
Buttons

Live Q&A: Health Equity in the Context of New and Emerging Therapies for Hemophilia

In this 30-minute CME Outfitters Live Q&A, experts in hemophilia will discuss questions related to new and emerging therapies that address health equity regarding hemophilia subtype as well as strategies to factor in racial and ethnic equity in the care of patients with hemophilia.

Buttons

Does Labeling the Level of Severity in Hemophilia Block Access to Optimized Care?

In this 30-minute CME Snack video, experts in hemophilia explore new and emerging therapies that can improve outcomes for patients with hemophilia. A case study presentation provides additional clinical perspective and offers ways to provide equitable treatment in underserved patient groups.

Buttons

Racial and Ethnic Disparities and Health Inequities in Multiple Myeloma

In this CME Outfitters podcast, expert faculty will review recent data and discuss the sweeping impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma.

Buttons

Hemostasis 2.0: Rethinking Hemophilia Management and Monitoring with Anti-TFPIs and FVIII Mimetics

/*! elementor - v3.22.0 - 24-06-2024 */ .elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px} Hemostasis 2.0: Rethinking Hemophilia Management and Monitoring with Anti-TFPIs and FVIII Mimetics /*! elementor - v3.22.0 - 24-06-2024 */ .elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor…